Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA; Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA; Sealy Institute for Drug Discovery, University of Texas Medical Branch, Galveston, TX, USA.
Antiviral Res. 2022 Nov;207:105423. doi: 10.1016/j.antiviral.2022.105423. Epub 2022 Sep 27.
Infections with mosquito-borne flaviviruses, such as Dengue virus, ZIKV virus, and West Nile virus, pose significant threats to public health. Flaviviruses cause up to 400 million infections each year, leading to many forms of diseases, including fatal hemorrhage, encephalitis, congenital abnormalities, and deaths. Currently, there are no clinically approved antiviral drugs for the treatment of flavivirus infections. The non-structural protein NS4B is an emerging target for drug discovery due to its multiple roles in the flaviviral life cycle. In this review, we summarize the latest knowledge on the structure and function of flavivirus NS4B, as well as the progress on antiviral compounds that target NS4B.
蚊媒黄病毒感染，如登革热病毒、寨卡病毒和西尼罗河病毒，对公共卫生构成重大威胁。黄病毒每年导致多达 4 亿例感染，导致多种疾病，包括致命性出血、脑炎、先天畸形和死亡。目前，尚无临床批准的抗病毒药物可用于治疗黄病毒感染。非结构蛋白 NS4B 是药物发现的一个新兴靶点，因为它在黄病毒生命周期中具有多种作用。在这篇综述中，我们总结了黄病毒 NS4B 的结构和功能的最新知识，以及针对 NS4B 的抗病毒化合物的进展。
